SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The intensity of competition after patent expiry in pharmaceuticals. A cross-country analysis
14 references·2 citing·40 second hop
The intensity of competition after patent expiry in pharmaceuticals. A cross-country analysis (2002)The intensity of competition after patent…Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals (2000)Pharmaceutical Policies in OE…Global Competitiveness in Pharmaceuticals: A European Perspective (2000)Global Competitiveness in Pha…Generic take-up in the pharmaceutical market following patent expiry (2000)Generic take-up in the pharma…Cross-national price differences for pharmaceuticals: how large, and why? (2000)Cross-national price differen…The role of economic evaluation in the pricing and reimbursement of medicines (1997)The role of economic evaluati…Generic Entry and the Pricing of Pharmaceuticals (1997)Generic Entry and the Pricing…Longer Patents for Increased Generic Competition in the US (1996)Longer Patents for Increased …Pricing, Profits, and Technological Progress in the Pharmaceutical Industry (1993)Pricing, Profits, and Technol…Pricing, Patent Loss and the Market for Pharmaceuticals (1992)Pricing, Patent Loss and the …Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)Brand Loyalty, Entry, and Pri…Pricing, Patent Loss and the Market For Pharmaceuticals (1991)Pricing, Patent Loss and the …Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals (1988)Persuasion or Information? Pr…The political economy of the pharmaceutical industry. (1986)The political economy of the …Price and Quality Competition in the United States Drug Industry (1978)Price and Quality Competition…Économie de la santé dans les pays en développement des paradigmes en mutation (2009)Économie de la santé dans les…TRIPS and the international public health controversies: issues and challenges (2006)TRIPS and the international p…Optimal Advertising and Optimal Quality (1976)Monopolistic Competition with Outside Goods (1979)Product differentiation advantages of pioneering brands (1980)Generic entry, price competition, and market segmentation in the prescription drug market (2007)Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation? (2008)Economics of the Pharmaceutical Industry (2018)Industrial research and technological innovation (1968)Social and Private Rates of Return from Industrial Innovations* (1977)The Rate of Obsolescence Of Knowledge, Research Gestation Lags, and the Private Rate of Return to Research Resources (1979)Foreign entry and survival: Effects of strategic choices on performance in international markets (1995)The Impact of Acquisitions on Innovation: Poison Pill, Placebo, or Tonic? (2004)Against Intellectual Monopoly (2008)Econometric Measurement of the Duration of Advertising Effect on Sales (1976)Medical Innovation Revisited: Social Contagion versus Marketing Effort (2001)The economic analysis of advertising (2005)Chapter 28 The Economic Analysis of Advertising (2007)Cost of innovation in the pharmaceutical industry (1991)Medical Care Costs: How Much Welfare Loss? (1992)Review of the literature on reference pricing (2000)Economic and Political Weekly (2017)Industrial Market Structure and Economic Performance. (1971)Killer Acquisitions (2020)Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry (1991)Generic Drug Industry Dynamics (2005)How Do Complementors Respond to the Threat of Platform Owner Entry? Evidence from the Mobile App Market (2016)Indexing and active fund management: International evidence (2016)Male-Female Wage Differentials in Urban Labor Markets (1973)Labor Market Discrimination Against Hispanic and Black Men (1983)Does Regulation Drive Out Competition in Pharmaceutical Markets? (2000)The Hedonic Method (2003)Parallel imports and the pricing of pharmaceutical products: evidence from the European Union (2004)Limit Pricing and Entry under Incomplete Information: An Equilibrium Analysis (1982)The Theory of Industrial Organization (1988)Generic Competition in the US Pharmaceutical Industry (2006)The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug Purchasing (2006)A DYNAMIC OLIGOPOLY STRUCTURAL MODEL FOR THE PRESCRIPTION DRUG MARKET AFTER PATENT EXPIRATION* (2010)Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States (2016)Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry (2016)The role of firm characteristics in pharmaceutical product launches (2006)Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries (2014)
this work references cited by second hop

References

  • 1992Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act574 cited
  • 1997Generic Entry and the Pricing of Pharmaceuticals388 cited
  • 2000Cross-national price differences for pharmaceuticals: how large, and why?285 cited
  • 1993Pricing, Profits, and Technological Progress in the Pharmaceutical Industry255 cited
  • 1988Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals254 cited
  • 1992Pricing, Patent Loss and the Market for Pharmaceuticals176 cited
  • 1986The political economy of the pharmaceutical industry.169 cited
  • 1991Pricing, Patent Loss and the Market For Pharmaceuticals157 cited
  • 1996Longer Patents for Increased Generic Competition in the US136 cited
  • 2000Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals135 cited
  • 2000Global Competitiveness in Pharmaceuticals: A European Perspective135 cited
  • 1997The role of economic evaluation in the pricing and reimbursement of medicines130 cited
  • 2000Generic take-up in the pharmaceutical market following patent expiry92 cited
  • 1978Price and Quality Competition in the United States Drug Industry64 cited

Cited by

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

2006
TRIPS and the international public health controversies: issues and challenges
55 cited
  • 2009Économie de la santé dans les pays en développement des paradigmes en mutation18 cited